World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management
William Shomali(Stanford Medicine), Jason Gotlib(Stanford University)
Cited by 191
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
|Haematologica|2015|252
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management
|American Journal of Hematology|2021|172
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
|Haematologica|2013|162
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2024|116